PARIS: Hopes of getting a treatment for coronavirus suffered a setback after French pharmaceutical giant Sanofi announced on Tuesday that it was halting of Phase 3 clinical tests of its Kevzara drug for serious COVID-19 cases as they had found inconclusive results .
The Phase 3 test — normally the last before official approval for use — “did not meet the primary or secondary evaluation criteria compared with a placebo, and in both cases, compared with established hospital care,” it said in a statement.
Sanofi said neither it nor its American partner in developing the drug, Regeneron, “envisage further clinical tests of Kevzara for the treatment of Covid-19.”